News

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

  • ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced the closing of its previously announced public offering of 8,500,000 shares of its common stock at a public offering price of $0.20 per share. Gross proceeds from the offering are $1.7 million before deducting placement agent fees and offering expenses. Virios Therapeutics intends to use the net proceeds of the offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study and for general corporate purposes.
    05/22/2024

US Stocks Mixed; Li Auto Shares Plummet After Q1 Results

  • U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 0.5% on Monday. Following the market opening Monday, the Dow traded down 0.19% to 39,925.91 while the NASDAQ rose 0.50% to 16,769.45. The S&P 500 also rose, gaining, 0.19% to 5,313.25. Check This Out: Top 3 Financial Stocks That Are Set To Fly This Quarter Information technology shares rose by 0.9% on Monday. In trading on Monday, real estate shares fell by 0.6%. Shares of The company posted revenue growth of 36.4% year-on-year to $3.55 billion, missing the analyst consensus estimate of $3.84 billion. Adjusted net earnings per ADS was 17 cents missed the analyst consensus estimate of 35 cents. GT Biopharma, Inc. GTBP+161.4%+ Free Alerts shares shot up 142% to $7.54. GT Biopharma, last week, posted a narrower-than-expected quarterly loss. Shares of Tantech Holdings Ltd TANH+79.5%+ Free Alerts got a boost, surging 119% to $1.44. MultiMetaVerse Holdings Limited MMV+187.8%+ Free Alerts shares were also up, gaining 102% to $1.25. MultiMetaVerse Holdings signed a non-binding term sheet to acquire 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries. Virios Therapeutics, Inc. VIRI-47.9%+ Free Alerts shares dropped 49% to $0.1790 after the company priced a $1.7 million pubic offering of 8.5 million shares of common stock at $0.20 per share. Shares of Akoustis Technologies, Inc. AKTS-44.7%Get Free Report were down 47% to $0.1899 after Qorvo won a jury verdict against the company in a trade secret misappropriation and patent infringement case. Jaguar Health, Inc JAGX-43.9%Get Free Report was down, falling 44% to $0.1457 after the company announced a 1-for-60 reverse stock split. Also Check This Out: This Analyst With 85% Accuracy Rate Sees Around 8% Upside In NVIDIA – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts In commodity news, oil traded down 0.4% to $79.74 while gold traded up 0.8% at $2,436.90. Silver traded up 1.9% to $31.84 on Monday, while copper rose 0.7% to $5.0860. European shares were higher today. The eurozone's STOXX 600 gained 0.2%, Germany's DAX rose 0.4% and France's CAC 40 climbed 0.5%. Spain's IBEX 35 Index rose 0.2%, while London's FTSE 100 rose 0.3%. Spain’s consumer confidence indicator climbed to 84.5 in April compared to 82.5 in March. The construction output in Italy rose by 3.8% year-over-year in March. Asian markets closed higher on Monday, with Japan's Nikkei gaining 0.73%, China's Composite Index climbing 0.54%, Hong Kong's Hang Seng Index gaining 0.42% and India's S&P BSE Sensex gaining 0.46%. Hong Kong's unemployment rate came in unchanged at 3% in the three months ending April 2024. Malaysia’s trade surplus shrank to MYR 7.7 billion in April from MYR 12.6 billion in the year-ago month. The People’s Bank of China held key lending rates at the recent fixing. No major economic reports will be released today. Now Read This: Insiders Buying Sempra And 2 Other Stocks
    05/20/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Virios Therapeutics, Inc. (VIRI) can hold. Click on Rating Page for detail.

The price of Virios Therapeutics, Inc. (VIRI) is 0.2564 and it was updated on 2024-07-19 09:01:01.

Currently Virios Therapeutics, Inc. (VIRI) is in undervalued.

News
    
News

Why Is Virios Therapeutics (VIRI) Stock Down 44% Today?

  • Virios Therapeutics (NASDAQ: VIRI ) stock is falling on Monday after the development-stage biotechnology company announced the pricing of a public offering for its shares. Virios Therapeutics is selling 8.5 million shares of VIRI stock at a price of 20 cents per share.
    Mon, May. 20, 2024

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

  • ATLANTA, May 19, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced the pricing of its previously announced public offering of 8,500,000 shares of its common stock at a public offering price of $0.20 per share. Gross proceeds from the offering are expected to be approximately $1.7 million before deducting placement agent fees and estimated offering expenses. The offering is expected to close on May 22, 2024, subject to customary closing conditions. Virios Therapeutics intends to use the net proceeds of the proposed offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study and for general corporate purposes.
    Sun, May. 19, 2024

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

  • ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced that it intends to offer and sell up to $2.1 million in shares of its common stock in a public offering. All shares of common stock in the offering are to be offered by Virios Therapeutics. Virios Therapeutics intends to use the net proceeds of the proposed offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study and for general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
    Fri, May. 17, 2024

Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript

  • Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Angela Walsh - Senior Vice President of Finance, Secretary & Treasurer Greg Duncan - Chief Executive Officer & Chairman of the Board of Directors Conference Call Participants David Bautz - Zacks Small-Cap Research Operator Good morning, and welcome to the Virios Therapeutics Incorporated First Quarter 2024 Earnings Call. At this time, all participants have been placed on a listen-only mode.
    Sat, May. 11, 2024

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

  • - Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 -
    Thu, May. 09, 2024
SEC Filings
SEC Filings

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 02/28/2024

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 08/22/2023

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 08/18/2023

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 06/20/2023

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 12/14/2022

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 12/12/2022

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 06/30/2022

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 05/24/2022

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 05/19/2022

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 05/18/2022

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 03/30/2022

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 03/24/2022

Virios Therapeutics, Inc. (VIRI) - 5

  • SEC Filings
  • 02/14/2022

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 01/28/2022

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 01/07/2022

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 01/05/2022

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 01/04/2022

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 12/23/2021

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 12/22/2021

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 07/09/2021

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 06/23/2021

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 06/22/2021

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 04/07/2021

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 04/06/2021

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 02/01/2021

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 01/12/2021

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 01/08/2021

Virios Therapeutics, Inc. (VIRI) - 4

  • SEC Filings
  • 12/21/2020

Virios Therapeutics, Inc. (VIRI) - 3

  • SEC Filings
  • 12/17/2020

Virios Therapeutics, Inc. (VIRI) - 3

  • SEC Filings
  • 12/16/2020
Press Releases
StockPrice Release
More Headlines
News

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

  • ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update.
  • 05/02/2024

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

  • - New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms – ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc.  (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including  fibromyalgia  (“FM”) and Long-COVID (“LC”), today announced that the World Intellectual Property Organization (WIPO) has published Virios' global patent application titled “Valacyclovir and Celecoxib for the Treatment of Alzheimer's and COVID-19”, which covers the use of IMC-2, a proprietary combination of valacyclovir and celecoxib. This milestone enables Virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.
  • 03/26/2024

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

  • ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • 02/29/2024

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

  • ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today issued a Shareholder Letter highlighting the Company's progress and key milestones in 2024.
  • 02/28/2024

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

  • - Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 - - Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 -
  • 01/22/2024

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

  • ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc.  (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced receipt of the Food and Drug Administration's (“FDA”) feedback on requirements for advancing IMC-2 (combination of valacyclovir + celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC illness, also known as post-acute sequelae of SARS-CoV-2 infection (“PASC”).
  • 01/02/2024

Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript

  • Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Greg Duncan - CEO Angela Walsh - SVP, Finance & Treasurer Mike Gendreau - CMO Conference Call Participants David Bautz - Zacks Small Cap Research Sean Lee - H.C. Wainwright Operator Good day, and welcome to the Virios Therapeutics, Inc. Third Quarter 2023 Earnings Update.
  • 11/13/2023

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

  • - Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the third quarter ended September 30, 2023.
  • 11/13/2023

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

  • ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, announced today that it will report third quarter 2023 financial results on Monday, November 13, 2023 before the open of the financial markets. Management will also host a webcast and conference call on November 13, 2023 at 8:30 a.m. ET to discuss the results and provide a corporate update.
  • 11/06/2023

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

  • ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the annual ThinkEquity Conference on Thursday, October 19, 2023 at 11:00 am ET in New York, NY.
  • 10/12/2023

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

  • ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, today announced that it provided notice of termination of the Capital on Demand™ Sales Agreement entered into between the Company and JonesTrading Institutional Services LLC on July 14, 2023 (the “Sales Agreement”). The Company has initiated the 10-day termination process under the Sales Agreement, with the official termination taking effect on September 28, 2023. The Company will make no sales under the Sales Agreement during this period.
  • 09/18/2023

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

  • ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors on Monday, September 18, 2023, at 11:00 am ET.
  • 09/12/2023

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

  • ATLANTA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID, today announced that it has advised its sales agent, JonesTrading Institutional Services LLC (“JonesTrading”), to cease sales under the Capital on Demandtm Sales Agreement entered into between the Company and JonesTrading on July 14, 2023.
  • 08/14/2023

Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript

  • Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Angela Walsh - Senior Vice President, Finance & Treasurer Greg Duncan - Chief Executive Officer Mike Gendreau - Chief Medical Officer Conference Call Participants David Bautz - Zacks Small Cap Research Sean Lee - H.C. Wainwright Operator Good day, and welcome to the Virios Therapeutics, Inc. Q2 2023 Earnings Update.
  • 08/10/2023

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

  • - Continued Progress in Expanding and Advancing Clinical Pipeline - - Conference Call Today at 8:30 a.m. ET -
  • 08/10/2023

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

  • ATLANTA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID, today announced that the Food & Drug Administration (“FDA”) communicated that, following their initial review of the Company's chronic toxicology program, the program's studies appear adequate to support the safety of IMC-1 at the dose proposed by the Company for chronic use. With this critical feedback in hand, the Company plans to initiate its proposed pharmacokinetic and food effect study (“pK”) this year, while concurrently resubmitting a final Phase 3 program outline and study protocols for FDA review. Following completion of the pK study, the goal will be to begin enrollment in the first fibromyalgia Phase 3 safety and efficacy study in mid-2024.
  • 08/09/2023

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

  • ATLANTA, July 17, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that female patients diagnosed with Long-COVID illness, otherwise known as Post-Acute Sequelae of COVID-19 infection (“PASC”), exhibited clinically and statistically significant improvements in fatigue, pain, and symptoms of autonomic dysfunction and general well-being related to Long-COVID when treated open-label with a combination of valacyclovir and celecoxib (“Val/Cel”) for 14 weeks, as compared to a control cohort of female Long-COVID patients matched by age, gender and length of illness and treated with routine care. The statistically significant improvements in PASC symptoms and general health status were particularly encouraging given that the mean duration of Long-COVID illness was two years for both the treated and control cohort prior to enrollment in this trial.
  • 07/17/2023

VIRI Stock Earnings: Virios Beats EPS Estimates

  • Virios Therapeutics (NASDAQ: VIRI ) reported first quarter results for 2023. Virios reported a loss per share of 8 cents.
  • 05/11/2023

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

  • ATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023 before the open of the financial markets.
  • 05/04/2023

Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal

  • Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune response-triggered maladies. The company went public in December 2020.
  • 04/25/2023

Virios Therapeutics stock doubles as fibromyalgia program moves forward

  • Virios Therapeutics shares more than doubled after the biotechnology company announced that its proposed Phase 3 program featuring its lead development candidate IMC-1 for fibromyalgia has been considered acceptable based on initial feedback from the US Food and Drug Administration (FDA). IMC-1 is a novel, fixed-dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the company's end goal being the reduction of virally promoted fibromyalgia disease symptoms.
  • 04/25/2023

Why Is Virios Therapeutics (VIRI) Stock Up 92% Today?

  • Virios Therapeutics (NASDAQ: VIRI ) stock is rocketing higher on Tuesday following an update on its planned Phase 3 clinical trial of IMC-1. IMC-1 is Virios Therapeutics' lead drug candidate in development for the treatment of herpes virus replication.
  • 04/25/2023

4 Penny Stocks To Watch If You're Playing The “Stock Market Game”

  • Penny stocks, the stock market game & what traders are watching this week. The post 4 Penny Stocks To Watch If You're Playing The “Stock Market Game” appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 04/10/2023

Best Penny Stocks To Buy Now? 10 To Watch Under $5

  • Penny stocks to watch this week under $5 The post Best Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 03/24/2023

Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023

  • ATLANTA, March 07, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), announced today that it will report fourth quarter and full year 2022 financial results on Tuesday, March 14, 2023 before the open of the financial markets.
  • 03/07/2023

Penny Stocks To Buy? 3 Stocks Under $1 To Watch Now

  • Penny stocks under $1 to watch this month. The post Penny Stocks To Buy?
  • 01/05/2023

Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

  • ATLANTA--( BUSINESS WIRE )--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Planet MicroCap Showcase, which is taking place virtually December 6 – 8, 2022.
  • 11/29/2022

Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q3 2022 Results - Earnings Call Transcript

  • Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Greg Duncan - CEO Ralph Grosswald - SVP, Operations Angela Walsh - SVP, Finance & Treasurer Dr. Mike Gendreau - Chief Medical Officer Conference Call Participants Sean Lee - H.C. Wainwright & Co., LLC Operator Good day, and welcome to the Virios Therapeutics, Inc. Q3 Earnings Update.
  • 11/14/2022

Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its third quarter 2022 financial results will be reported on Monday, November 14, 2022 before the open of the financial markets.
  • 11/03/2022

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

  • The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.
  • 10/24/2022

These Were The Five Best And Worst Performing Healthcare Stocks In September 2022

  • September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
  • 10/17/2022

Why Is Virios Therapeutics (VIRI) Stock Down 71% Today?

  • Source: Shutterstock / PopTika Virios Therapeutics (NASDAQ: VIRI ) stock is falling hard on Monday after the company revealed results from its Phase 2b Study of IMC-1 in Fibromyalgia. IMC-1 is a treatment in development by the company for people suffering from Fibromyalgia.
  • 09/19/2022

Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q2 2022 Results - Earnings Call Transcript

  • Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET CompanyParticipants Greg Duncan - CEO Ralph Grosswald - SVP, Operations Angela Walsh - SVP, Finance & Treasurer Conference Call Participants David Bautz - Zacks Small Cap Research Sean Lee - H.C. Wainwright & Co., LLC Operator Good morning, and welcome to the Virios Therapeutics, Inc. Second Quarter 2022 Financial Results Conference Call.
  • 08/13/2022

Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its second quarter 2022 financial results will be reported on Thursday, August 11, 2022 before the open of the financial markets. Management will also host a webcast and conference call on August 11, 2022 at 8:30 a.m. ET to discuss the results
  • 08/04/2022

Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q1 2022 Results - Earnings Call Transcript

  • Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Angela Walsh - Senior Vice President of Finance, and Treasurer Greg Duncan - Chief Executive Officer Ralph Grosswald - Senior Vice President of Operations Conference Call Participants David Bautz - Zacks Research Operator Good morning, and welcome to the Virios Therapeutics, Incorporated First Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please be advised that today's call is being recorded at the company's request.
  • 05/13/2022

Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its first quarter 2022 financial results will be reported on Thursday, May 12, 2022 before the open of the financial markets. Management will also host a webcast and conference call on May 12, 2022 at 8:30 a.m. ET to discuss the results and pro
  • 05/05/2022

Virios Therapeutics' (VIRI) CEO Greg Duncan on Q4 2021 Results - Earnings Call Transcript

  • Virios Therapeutics' (VIRI) CEO Greg Duncan on Q4 2021 Results - Earnings Call Transcript
  • 03/17/2022

Virios Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 17, 2022

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia, announced today that its fourth quarter and full year 2021 financial results will be reported on Thursday, March 17, 2022 before the open of the financial markets. Management will also host a webcast and conference call on March 17, 2022 at 8:30 a.m. ET to discuss the results and provide a
  • 03/10/2022

Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022. The presentation will focus on the role of activated viruses triggering a
  • 01/04/2022

Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q3 2021 Results - Earnings Call Transcript

  • Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q3 2021 Results - Earnings Call Transcript
  • 11/11/2021

Virios Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Thursday, November 11, 2021

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain and fatigue related diseases, announced today that its third quarter 2021 financial results will be reported on Thursday, November 11, 2021 before the open of the financial markets. Management will also host a webcast and conference call on November 11, 2021 at 8:30 a.m. ET to discuss the results and provide a corporat
  • 11/04/2021

VIRI Stock: Over 5% Increase Pre-Market Explanation

  • The stock price of Virios Therapeutics LLC (NASDAQ: VIRI) increased by over 5% pre-market. This is why it happened.
  • 09/08/2021

Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Antiviral--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, announced today that the United States Patent and Trademark Office (“USPTO”) has granted Virios Therapeutics patent exclusivity on its valacyclovir-celecoxib combination drug candidate to 2033. The Company's intellectual property portfolio now includes 21 issued patents, consisting of 13 iss
  • 09/08/2021

Virios Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference which is taking place virtually September 13 – 15, 2021. The presentation will focus on the role of activated viruses trigge
  • 09/02/2021

Virios Therapeutics Announces New Social Media Profiles

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today the expansion of the company's social media platforms as well as social media disclosure. Virios has established a social presence on LinkedIn, Twitter and Facebook, where current and potential investors and other interested persons can connect with the company and receive future updates.
  • 08/19/2021

Virios Therapeutics CEO Highlights Novel Therapeutic Approach for Treating Fibromyalgia and Irritable Bowel Syndrome in Stock News Now Video Interview

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that Chairman and CEO, Greg Duncan, highlighted the Company's novel combination antiviral development approach, its ongoing Phase 2b trial Fibromyalgia trial and plans for expanded pipeline programs in irritable bowel syndrome (IBS) and fatigue related disorders during a video interview w
  • 08/16/2021

Virios Therapeutics' (VIRI) CEO Greg Duncan on Q2 2021 Results - Earnings Call Transcript

  • Virios Therapeutics' (VIRI) CEO Greg Duncan on Q2 2021 Results - Earnings Call Transcript
  • 08/12/2021

Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “Our landmark Phase 2b fibromyalgia clinical trial, referred to as FORTRESS, has rapidly progressed and patients are being enrolled at more than 40 clinical trial sites, keeping us on track to ann
  • 08/12/2021

Virios Therapeutics to Present at the SNN Network Summer Virtual Conference

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the SNN Network Summer Virtual Conference on August 19, 2021 at 9:00 a.m. ET. The presentation will focus on the role of activated viruses triggering a wide range of conditions, including fibromyalg
  • 08/11/2021

Virios Therapeutics Featured in Bloomberg TV Interview

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that an interview with Chairman and CEO, Greg Duncan, was aired on Bloomberg TV during The RedChip Money Report®, which delivers commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public compan
  • 08/09/2021

Virios Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Thursday, August 12, 2021

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that its second quarter 2021 financial results will be reported on Thursday, August 12, 2021 before the open of the financial markets. Management will also host a webcast and conference call on August 12, 2021 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live
  • 08/05/2021

VIRI Stock Increases Over 6% Pre-Market: Why It Happened

  • The stock price of Virios Therapeutics LLC (NASDAQ: VIRI) increased by over 6% pre-market. This is why it happened.
  • 07/26/2021

Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA “Fast Track” Review Designated Antiviral Therapy, Oral IMC-1

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #fibromyalgia--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain and fatigue related diseases, announced today that all 41 sites involved in its ongoing 460 patient Phase 2b fibromyalgia (FM) trial are now fully activated and enrolling patients. This trial builds on the encouraging results from the Company's previously completed IMC-1 phase 2a FM clinical study. The 143-patient Phase 2
  • 07/26/2021

Virios Therapeutics Stock Moves Higher On Promising IMC-1 Safety Data In Mid-Stage Fibromyalgia Trial

  • Virios Therapeutics Inc (NASDAQ: VIRI) has announced that data from its Phase 2a PRID-201 trial demonstrated that IMC-1 was better tolerated than placebo in patients with fibromyalgia. The disease is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues.
  • 06/09/2021

Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress

  • ATLANTA--(BUSINESS WIRE)---- $VIRI #IASP2021--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that data from the company's Phase 2a clinical trial PRID-201 demonstrated that IMC-1 was better tolerated than placebo in patients with fibromyalgia (“FM”). This result is highlighted in a poster presentation at the International Association fo
  • 06/09/2021

Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today dosing of the first patient in its Phase 2b clinical trial, referred to as FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1), evaluating IMC-1 in patients with fibromyalgia. IMC-1 is a novel, proprietary,
  • 06/04/2021

Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints at the EULAR European Congress of Rheumatology

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that clinical data from its Phase 2a trial of IMC-1 in fibromyalgia (“FM”) is featured in a poster presentation (poster POS0017) at the annual EULAR European Congress of Rheumatology, a renowned forum for interaction between medical doctors, sci
  • 06/02/2021

Virios Therapeutics Announces Oral Presentation of Clinical Data at Digestive Disease Week® (DDW)

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that clinical data was highlighted in an oral presentation at Digestive Disease Week® (“DDW”) 2021, the premier global meeting for physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal
  • 05/24/2021

Virios Therapeutics (VIRI) Stock: Over 20% Increase Explanation

  • The stock price of Virios Therapeutics (NASDAQ: VIRI) increased by over 20% during intraday trading. This is why it happened.
  • 05/18/2021

Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q1 2021 Results - Earnings Call Transcript

  • Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q1 2021 Results - Earnings Call Transcript
  • 05/13/2021

Virios Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported financial results for the first quarter ended March 31, 2021. “Our team has made significant operational progress to ensure the commencement of our landmark Phase 2b fibromyalgia clinical trial, referred to as FORTRESS (Fibromyalgia Outcome Resea
  • 05/13/2021

Virios Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on Thursday, May 13, 2021

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that its first quarter 2021 financial results will be reported on Thursday, May 13, 2021 before the open of the financial markets. Management will also host a webcast and conference call on May 13, 2021 at 8:30 a.m. ET to discuss the results and
  • 05/06/2021

Virios Therapeutics to Present at the Needham Virtual Healthcare Conference

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman and Chief Executive Officer, and R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer, will present a company overview at the Needham Virtual Healthcare Conference on April 14, 2021 at 4:30 p.m. ET. The presentation
  • 04/07/2021

Virios Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update. “Since our initial public offering in December 2020, the Virios Therapeutics team has made significant operational progress to ensure the c
  • 03/18/2021

Virios Therapeutics: Highly Differentiated Mechanism Of Action In Fibromyalgia

  • Virios Therapeutics: Highly Differentiated Mechanism Of Action In Fibromyalgia
  • 03/15/2021

Virios Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Thursday, March 18, 2021

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that its fourth quarter and full year 2020 financial results will be reported on Thursday, March 18, 2021 before the open of the financial markets. Management will also host a webcast and conference call on March 18, 2021 at 8:30 a.m. ET to disc
  • 03/11/2021

Virios Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in March 2021

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Life Sciences Conference, which is taking place March 9 - 10, 2021. The presentation will focus on the need for new approaches
  • 02/24/2021

7 Stocks With Insider Buying

  • Insider buying could be a bullish signal for a stock. Why? The insiders may sell for a number of reasons.
  • 02/05/2021

Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS). The first step in the collaboration is focused on designing a phase 2 proof of concept study to tre
  • 02/01/2021

Virios Therapeutics to Present at the BIO CEO & Investor Conference

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the virtual 2021 BIO CEO & Investor Conference to be held from February 16-18, 2021. The presentation will focus on the need for new approaches to treat fibromyalgia (“FM”
  • 01/28/2021

Virios Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-Allotment Option

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, today announced the closing of its initial public offering of 3,450,000 shares of its common stock at a public offering price of $10.00 per share, which includes 450,000 shares sold upon full exercise of the underwriter's option to purchase additional common shares. The gross proce
  • 12/21/2020

Virios Therapeutics Announces Pricing of Initial Public Offering

  • ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (the “Company”), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $30 million, before deducting underwriting discounts, commissions and offering expenses. In addition, the Compan
  • 12/16/2020
Unlock
VIRI Ratings Summary
VIRI Quant Ranking